Compounds > azapetine
Page last updated: 2024-09-21

azapetine

Description

azapetine: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8966
CHEMBL ID2110596
CHEBI ID134955
SCHEMBL ID456796
MeSH IDM0045502

Synonyms (52)

Synonym
PDSP1_001659
ilidar base
azapetina [italian]
6-allyl-6,7-dihydro-5h-dibenz(c,e)azepine
6-allil-6,7-diidro-5h-dibenzo(c,l)azepina [italian]
5h-dibenz(c,e)azepine, 6,7-dihydro-6-allyl-
einecs 205-667-3
azapetine
brn 0194617
5h-dibenz(c,e)azepine, 6-allyl-6,7-dihydro-
5h-dibenz[c,e]azepine, 6,7-dihydro-6-(2-propenyl)-
D07178
azapetine (ban)
146-36-1
PDSP2_001643
CHEBI:134955
6-prop-2-enyl-5,7-dihydrobenzo[d][2]benzazepine
L000884
cas_130-83-6
nsc_8966
bdbm81805
6-allyl-6,7-dihydro-5h-benzo[d][2]benzazepine
azapetine [ban]
6-allil-6,7-diidro-5h-dibenzo(c,l)azepina
azapetina
9ttr0ua2kc ,
unii-9ttr0ua2kc
azapeptine
CHEMBL2110596
azapetine [who-dd]
5h-dibenz(c,e)azepine, 6,7-dihydro-6-(2-propenyl)-
SCHEMBL456796
MLS006011552
smr004703318
6-allyl-6,7-dihydro-5h-dibenzo[c,e]azepine #
NYGHGTMKALXFIA-UHFFFAOYSA-N
1-allyl-2,7-dihydro-3,4:5,6-dibenzazepine
ilidar (salt/mix)
5h-dibenz[c,e]azepine, 6-allyl-6,7-dihydro-
DTXSID50163250
AKOS027381702
6-allyl-6,7-dihydro-5h-dibenz[c,e]azepine
SR-01000945198-2
sr-01000945198
SR-01000945198-1
6-allyl-6,7-dihydro-5h-dibenzo[c,e]azepine
DB13727
Q738815
5h-dibenz[c,e]azepine, 6,7-dihydro-6-(2-propen-1-yl)-
STARBLD0009513
EN300-26271786
9-(prop-2-en-1-yl)-9-azatricyclo[9.4.0.0,2,7]pentadeca-1(15),2,4,6,11,13-hexaene

Drug Classes (1)

ClassDescription
benzazepineA group of two-ring heterocyclic compounds consisting of a benzene ring fused to an azepine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.20500.00021.874210.0000AID167197
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.20500.00021.270410.0000AID167197
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.20500.00001.819410.0000AID167197
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Kd0.81280.00020.52667.5858AID196984
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)Kd13.18260.00020.62779.3325AID196987
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)Kd13.18260.00020.62779.3325AID196987
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)Kd13.18260.00020.62779.3325AID196987
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)Kd0.81280.00020.89627.5858AID196984
Alpha-1D adrenergic receptorHomo sapiens (human)Kd0.10970.00000.19451.2882AID166825
Alpha-1A adrenergic receptorHomo sapiens (human)Kd0.10970.00000.20481.2882AID166825
Alpha-1B adrenergic receptorHomo sapiens (human)Kd0.10970.00000.11991.2882AID166825
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Kd0.81280.00020.51397.5858AID196984
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (37)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
apoptotic processAlpha-1A adrenergic receptorHomo sapiens (human)
smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
activation of phospholipase C activityAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1A adrenergic receptorHomo sapiens (human)
adult heart developmentAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of cell population proliferationAlpha-1A adrenergic receptorHomo sapiens (human)
response to xenobiotic stimulusAlpha-1A adrenergic receptorHomo sapiens (human)
response to hormoneAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of autophagyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of action potentialAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
calcium ion transport into cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
cell growth involved in cardiac muscle cell developmentAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase C signalingAlpha-1A adrenergic receptorHomo sapiens (human)
pilomotor reflexAlpha-1A adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-1B adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of cardiac muscle contractionAlpha-1B adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1B adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1B adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1B adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1B adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
nucleusAlpha-1A adrenergic receptorHomo sapiens (human)
nucleoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
caveolaAlpha-1A adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
nucleusAlpha-1B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
caveolaAlpha-1B adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID166825In vitro antagonist activity against (-)-phenylephrine or (-)-norepinephrine-induced alpha1-adrenoceptor-mediated vasoconstriction of rabbit isolated pulmonary artery.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID235864Index of alpha1/alpha2 adrenoceptor antagonist selectivity at post junctional vascular sites in vivo.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID235866Index of alpha1/alpha2 adrenoceptor binding selectivity.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID36923Inhibition of specific [3H]clonidine binding (0.4 nM) to rat brain membranes alpha-2 adrenergic receptor1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID196984Antagonist activity against phenylephrine-induced alpha1- adrenoceptor mediated vasoconstriction in pithed normotensive rats. 1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID235865Index of alpha1/alpha2 adrenoceptor antagonist selectivity at pre and postsynaptic sites in vitro.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID167197Inhibition of specific [3H]-prazosin binding (0.2 nM) to rat brain membranes alpha-1 adrenergic receptor1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID196987Antagonist activity against B-HT 933-induced alpha-2-adrenoceptor-mediated vasoconstriction in pithed normotensive rats1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID166854Antagonist activity against norepinephrine-induced alpha-2-adrenoceptor-mediated vasoconstriction of rabbit isolated pulmonary artery.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-199035 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
7-hydroxy-2-n,n-dipropylaminotetralin[no description available]medium10tetralins
brimonidine[no description available]medium10imidazoles;
quinoxaline derivative;
secondary amine		adrenergic agonist;
alpha-adrenergic agonist;
antihypertensive agent
cirazoline[no description available]medium10aromatic ether
clonidine[no description available]medium30clonidine;
imidazoline
mianserin[no description available]medium10dibenzoazepineadrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist
naphazoline[no description available]medium10naphthalenes
oxymetazoline[no description available]medium10carboxamidine;
imidazolines;
phenols		alpha-adrenergic agonist;
nasal decongestant;
sympathomimetic agent;
vasoconstrictor agent
prazosin[no description available]medium30aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
talipexole[no description available]medium10azepine
tetrahydrozoline[no description available]medium10carboxamidine;
imidazolines		nasal decongestant;
sympathomimetic agent
tolazoline[no description available]medium70imidazolesalpha-adrenergic antagonist;
antihypertensive agent;
vasodilator agent
tramazoline[no description available]medium10tetralins
xylazine[no description available]medium101,3-thiazine;
methylbenzene;
secondary amino compound		alpha-adrenergic agonist;
analgesic;
emetic;
muscle relaxant;
sedative
xylometazoline[no description available]medium10alkylbenzene
phentolamine[no description available]medium80imidazoles;
phenols;
substituted aniline;
tertiary amino compound		alpha-adrenergic antagonist;
vasodilator agent
piperoxan[no description available]medium10
phenylephrine[no description available]medium10phenols;
phenylethanolamines;
secondary amino compound		alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent
methoxamine[no description available]medium10amphetaminesalpha-adrenergic agonist;
antihypotensive agent
yohimbine[no description available]medium10methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist
dihydroergotamine[no description available]medium10ergot alkaloid;
semisynthetic derivative		dopamine agonist;
non-narcotic analgesic;
serotonergic agonist;
sympatholytic agent;
vasoconstrictor agent
amidephrine[no description available]medium10sulfonamide
lofexidine[no description available]medium10aromatic ether;
carboxamidine;
dichlorobenzene;
imidazoles		alpha-adrenergic agonist;
antihypertensive agent
5,6-dihydroxy-2-dimethylaminotetralin[no description available]medium10tetralins
tiamenidine[no description available]medium10organochlorine compound
corynanthine[no description available]medium10yohimban alkaloid
st 587[no description available]medium10
indanidine[no description available]medium10
2-(n,n-dipropyl)amino-5,6-dihydroxytetralin[no description available]medium10
(3,4-dihydroxyphenylamino)-2-imidazoline[no description available]medium10
2-(n,n-dipropyl)amino-6,7-dihydroxytetralin[no description available]medium10
5-hydroxy-2-n,n-dipropylaminotetralin[no description available]medium10
rauwolscine[no description available]medium10methyl 17-hydroxy-20xi-yohimban-16-carboxylate
guanabenz[no description available]medium10dichlorobenzene
clozapine[no description available]medium20benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
phenoxybenzamine[no description available]medium60aromatic amine
oxytocin[no description available]medium10heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
sulpiride[no description available]medium10benzamides;
N-alkylpyrrolidine;
sulfonamide		antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
metoclopramide[no description available]medium10benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound		antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic
propranolol[no description available]medium20naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
chlorpromazine[no description available]medium10organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
haloperidol[no description available]medium10aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
desipramine[no description available]medium10dibenzoazepine;
secondary amino compound		adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor
dizocilpine maleate[no description available]medium10maleate salt;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
amphetamine[no description available]medium10primary amine
oxidopamine[no description available]medium10benzenetriol;
catecholamine;
primary amino compound		drug metabolite;
human metabolite;
neurotoxin
bis(4-methyl-1-homopiperazinylthiocarbonyl)disulfide[no description available]medium10
isoproterenol[no description available]medium10catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
dibenzylchlorethamine[no description available]medium10
galantamine[no description available]medium10benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound		antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite
sk&f 81297[no description available]low00benzazepine
sk&f 82958[no description available]low00benzazepine
sk&f 77434[no description available]low00benzazepine;
catechols;
tertiary amino compound		dopamine agonist
sk&f-38393[no description available]low00benzazepine;
catechols;
secondary amino compound
1h-3-benzazepin-7-ol, 8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-[no description available]low00benzazepine
epinastine[no description available]low00benzazepine;
guanidines		anti-allergic agent;
H1-receptor antagonist;
histamine antagonist;
ophthalmology drug
fenoldopam[no description available]low00benzazepinealpha-adrenergic agonist;
antihypertensive agent;
dopamine agonist;
dopaminergic antagonist;
vasodilator agent
mirtazapine[no description available]low00benzazepine;
tetracyclic antidepressant		alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
oneirogen;
serotonergic antagonist
7-chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol[no description available]low00benzazepine;
organochlorine compound;
tertiary amino compound		dopaminergic antagonist
fluperlapine[no description available]low00benzazepine
fenoldopam mesylate[no description available]low00benzazepine
zatebradine[no description available]low00benzazepine
ecopipam[no description available]low00benzazepine
sk&f 104078[no description available]low00benzazepine
sk&f 86466[no description available]low00benzazepine
nnc 112[no description available]low00benzazepine
ivabradine[no description available]low00aromatic ether;
benzazepine;
carbobicyclic compound;
tertiary amino compound		cardiotonic drug
sk&f 83959[no description available]low00benzazepine;
catechols;
organochlorine compound;
tertiary amino compound		dopamine agonist
conivaptan[no description available]low00benzazepineaquaretic;
vasopressin receptor antagonist
tolvaptan[no description available]low00benzazepine;
benzenedicarboxamide		aquaretic;
vasopressin receptor antagonist
sanguinine[no description available]low00benzazepine
lycoramine[no description available]low00benzazepine
7,8-dimethoxy-1,3-dihydro-3-benzazepin-2-one[no description available]low00benzazepine
5-Methyl-8-nitro-3-spirocyclohexyl-2,3,4,5-tetrahydro-1H-2-benzazepine[no description available]low00benzazepine
capsazepine[no description available]low00benzazepine;
catechols;
monochlorobenzenes;
thioureas		capsaicin receptor antagonist
sch 23390[no description available]low00benzazepine
ru 42173[no description available]low00benzazepine
benazepril[no description available]low00benzazepine;
dicarboxylic acid monoester;
ethyl ester;
lactam		EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
benazeprilat[no description available]low00benzazepine;
dicarboxylic acid;
lactam		EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
(5R)-9-bromo-5-phenyl-3-prop-2-enyl-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol[no description available]low00benzazepine
demethylmirtazapine[no description available]low00benzazepine;
tetracyclic antidepressant		alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
human xenobiotic metabolite;
serotonergic antagonist
lorcaserin[no description available]low00benzazepine;
organochlorine compound		anti-obesity agent;
appetite depressant
mln8054[no description available]low00benzazepine
mln 8237[no description available]low00benzazepine
evacetrapib[no description available]low00benzazepine
ConditionIndicatedRelationship StrengthStudiesTrials
Blood Pressure, High0low10
Depression, Endogenous0low10
Depression, Neurotic0low10
Depression, Unipolar0low10
Depressive Disorder0low10
Depressive Syndrome0low10
Disease0low20
Diseases, Peripheral Vascular0low120
Hypertension0low10
Kidney Diseases0low10
Melancholia0low10
Muscle Contraction0low20
Neurosis, Depressive0low10
Peripheral Angiopathies0low120
Peripheral Arterial Disease0low10
Peripheral Arterial Diseases0low10
Peripheral Artery Disease0low10
Peripheral Vascular Diseases0low120
Pregnancy0low10
Spinal Diseases0low10
Symptom Cluster0low10
Syndrome0low10
Unipolar Depression0low10
Vascular Diseases0low130
Vascular Diseases, Peripheral0low120